Logo image of MESO

MESOBLAST LTD- SPON ADR (MESO) Stock Overview

NASDAQ:MESO - US5907174016 - ADR

15.81 USD
+0.64 (+4.22%)
Last: 8/22/2025, 8:23:28 PM
15.7 USD
-0.11 (-0.7%)
After Hours: 8/22/2025, 8:23:28 PM

MESO Key Statistics, Chart & Performance

Key Statistics
52 Week High22
52 Week Low6
Market Cap2.01B
Shares127.00M
Float91.76M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.8
PEN/A
Fwd PEN/A
Earnings (Next)08-29 2025-08-29/amc
IPO12-16 2004-12-16
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


MESO short term performance overview.The bars show the price performance of MESO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30 40

MESO long term performance overview.The bars show the price performance of MESO in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of MESO is 15.81 USD. In the past month the price decreased by -3.36%. In the past year, price increased by 141.01%.

MESOBLAST LTD- SPON ADR / MESO Daily stock chart

MESO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.89 372.00B
AMGN AMGEN INC 13.47 157.94B
GILD GILEAD SCIENCES INC 14.83 142.77B
VRTX VERTEX PHARMACEUTICALS INC 23.32 101.30B
REGN REGENERON PHARMACEUTICALS 12.92 63.65B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.25B
ARGX ARGENX SE - ADR 71.2 40.39B
ONC BEONE MEDICINES LTD-ADR 5.78 37.29B
INSM INSMED INC N/A 27.88B
BNTX BIONTECH SE-ADR N/A 26.66B
NTRA NATERA INC N/A 22.61B
BIIB BIOGEN INC 8.7 20.42B

About MESO

Company Profile

MESO logo image Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 73 full-time employees. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.

Company Info

MESOBLAST LTD- SPON ADR

L 38 55 Collins St

Melbourne VICTORIA 3000 AU

CEO: Silviu Itescu

Employees: 73

MESO Company Website

MESO Investor Relations

Phone: 61396396036

MESOBLAST LTD- SPON ADR / MESO FAQ

What is the stock price of MESOBLAST LTD- SPON ADR today?

The current stock price of MESO is 15.81 USD. The price increased by 4.22% in the last trading session.


What is the ticker symbol for MESOBLAST LTD- SPON ADR stock?

The exchange symbol of MESOBLAST LTD- SPON ADR is MESO and it is listed on the Nasdaq exchange.


On which exchange is MESO stock listed?

MESO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MESOBLAST LTD- SPON ADR stock?

9 analysts have analysed MESO and the average price target is 16.19 USD. This implies a price increase of 2.39% is expected in the next year compared to the current price of 15.81. Check the MESOBLAST LTD- SPON ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MESOBLAST LTD- SPON ADR worth?

MESOBLAST LTD- SPON ADR (MESO) has a market capitalization of 2.01B USD. This makes MESO a Mid Cap stock.


How many employees does MESOBLAST LTD- SPON ADR have?

MESOBLAST LTD- SPON ADR (MESO) currently has 73 employees.


What are the support and resistance levels for MESOBLAST LTD- SPON ADR (MESO) stock?

MESOBLAST LTD- SPON ADR (MESO) has a support level at 14.69 and a resistance level at 16.19. Check the full technical report for a detailed analysis of MESO support and resistance levels.


Is MESOBLAST LTD- SPON ADR (MESO) expected to grow?

The Revenue of MESOBLAST LTD- SPON ADR (MESO) is expected to grow by 153.13% in the next year. Check the estimates tab for more information on the MESO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MESOBLAST LTD- SPON ADR (MESO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MESOBLAST LTD- SPON ADR (MESO) stock pay dividends?

MESO does not pay a dividend.


When does MESOBLAST LTD- SPON ADR (MESO) report earnings?

MESOBLAST LTD- SPON ADR (MESO) will report earnings on 2025-08-29, after the market close.


What is the Price/Earnings (PE) ratio of MESOBLAST LTD- SPON ADR (MESO)?

MESOBLAST LTD- SPON ADR (MESO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.8).


What is the Short Interest ratio of MESOBLAST LTD- SPON ADR (MESO) stock?

The outstanding short interest for MESOBLAST LTD- SPON ADR (MESO) is 2.59% of its float. Check the ownership tab for more information on the MESO short interest.


MESO Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to MESO. When comparing the yearly performance of all stocks, MESO is one of the better performing stocks in the market, outperforming 96.57% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MESO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MESO. MESO has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MESO Financial Highlights

Over the last trailing twelve months MESO reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 15.22% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -13.46%
ROE -19.07%
Debt/Equity 0.23
Chartmill High Growth Momentum
EPS Q2Q%-9.95%
Sales Q2Q%-6.85%
EPS 1Y (TTM)15.22%
Revenue 1Y (TTM)-21.32%

MESO Forecast & Estimates

9 analysts have analysed MESO and the average price target is 16.19 USD. This implies a price increase of 2.39% is expected in the next year compared to the current price of 15.81.

For the next year, analysts expect an EPS growth of -1.85% and a revenue growth 153.13% for MESO


Analysts
Analysts77.78
Price Target16.19 (2.4%)
EPS Next Y-1.85%
Revenue Next Year153.13%

MESO Ownership

Ownership
Inst Owners16.91%
Ins Owners18.01%
Short Float %2.59%
Short Ratio9.93